Home » FDA Denies Blueprint’s NDA for Stomach Cancer Treatment
FDA Denies Blueprint’s NDA for Stomach Cancer Treatment
The FDA has turned down a new drug application (NDA) from Blueprint Medicines for Ayvakit (avapritinib) for treatment of adults with unresectable or metastatic fourth-line gastrointestinal stromal tumor (GIST).
The agency approved the drug in January for treatment of GIST patients with a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation, a genetic alteration found in about 10 percent of GIST cases.
The company said it will continue to commercialize the drug for GIST patients with the exon 18 mutation.
Upcoming Events
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May